Table of Contents Table of Contents
Previous Page  686 / 812 Next Page
Information
Show Menu
Previous Page 686 / 812 Next Page
Page Background

S682

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

comorbid medical conditions, it can severely influence the desir-

able outcome.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2025

EV1041

Subacute psychiatric hospitalization

unit: The role of clozapine

O. Orejas

, C. M

asferrer Herrera , C. Macías Castellví ,

P. Flores Martínez

Neuropsychiatry and Addictions Institute INAD, Parc de salut Mar,

Psychiatry Hospitalization, Barcelona, Spain

Corresponding author.

Introduction

Several studies report that Clozapine is more effec-

tive in reducing symptoms of schizophrenia, producing clinically

meaningful improvements and postponing relapse than other

antipsychotic strategies.

Objectives

To analyze the prescription of Clozapine in a sample

of 88 inpatients admitted to a subacute psychiatric hospitalization

unit.

Methods

This is a transversal study. All patients admitted

for a medium-term psychiatric treatment since 01/06/2014 to

30/11/2015 were included. Data about socio-demographical status

and clinical situation were obtained and compiled in a database.

This study compares patients receiving clozapine treatment with

thosewho receive other psychopharmacologic treatment. Statistics

were performed using SPSS Software.

Results

Eighty-eight patients (52% men; mean age: 48.6 years)

composed the sample. In 58% of cases, schizophrenia and schizoaf-

fective disorder were the diagnoses motivating the admission.

Within the 51 patients with Schizophrenia o Schizoaffective Dis-

order, 16 of them (31.4%) received Clozapine. Comparing clozapine

group vs non-clozapine group, therewere no significant differences

between the groups in terms of sex, civil state or working state.

Instead, Clozapine group patients were older, had a major number

of previous hospitalization admissions and had a larger trajectory

of their disorder.

Conclusions

Patients requiring treatment with Clozapine had a

major number of hospital admissions and had more often com-

mitted suicide attempts, suggesting a more severe course of the

disorder. They were older than the non-clozapine group. Clozap-

ine is delayed in its use among resistant-treatment patients. It is

worth highlighting that only 16 cases of Schizophrenia inpatients

received Clozapina. It could mean that Clozapine is underpre-

scribed.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2026

EV1042

The treatment of autism with

pipamperone: A case report

B. Petrosino

1 ,

, M .S

. Signorelli

2 , F. M

agnano di San Lio

2 ,

C. Petrosino

3 , E. A

guglia

2

1

Psichiatria, Medicina clinica e sperimentale, Caltagirone, Italy

2

Psichiatria, Medicina Clinica e sperimentale, Catania, Italy

3

Psichiatria, ASP Catania, Caltagirone, Italy

Corresponding author.

Introduction

Adults with autism spectrum disorders (ASD) often

have behavioral disorders, like aggression, agitation and self-injury.

These problems are frequently severe enough to limit educational

and developmental progress. Only risperidone and aripiprazole

have so far been approved by the FDA for the treatment of behav-

ioral disturbance associated with autism. These drugs are not

very effective in the long term, with little benefits to the social

functioning and they are associated with side effects. This case

report describes the use of pipamperone, in treating behavioral

disorders of a patient with autism spectrum disorder and severe

mental retardation.

Case presentation

Here is presented the case of a 32-year-old

man with autism spectrum disorder, severe mental retarda-

tion (caused by undiagnosed phenylketonuria for the first 3

years of life) treated with antipsychotics since childhood. He

showed numerous episodes of psychomotor agitation, hetero-

direct physical aggression and self-injury, andmovement disorders

induced by drugs. Treatmentwithpipamperone reduced drastically

crises of psychomotor agitation, and behavioral disorders, without

extrapyramidal side effects, and led to an improvement in social

functioning. The control of behavioral symptoms associated with

adherence to treatment was maintained for 6-month follow up.

These clinical observations are supported by ratings using: ABC,

CGI-S and CGI-I, VABS, SAS, AIMS.

Conclusion

This case report provides the first potential evidence

that pipamperone may be effective in treating behavioral prob-

lems associated with autism spectrum disorders. Moreover, the

improvement of social functioning and the lack of extrapyrami-

dal side effects make this drug notable for its effectiveness and

tolerability.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2027

EV1043

Effect of metformin treatment on

metabolic parameters in atypical

antipsychotic-treated schizophrenic

patients

V. Prisco

1 ,

, S. Sorice

1

, F. Franza

2

, M. Fabrazzo

1

1

University of Naples SUN, Department of Psychiatry, Naples, Italy

2

Neuropsychiatric nursing home “Villa dei pini”, Avellino,

Department of Neuropsychiatry, Avellino, Italy

Corresponding author.

Few studies have compared the effect of Metformin treat-

ment on metabolic parameters in atypical antipsychotic-treated

schizophrenic patients. The present study examined metabolic

abnormalities due to clozapine or olanzapine in schizophrenic

patients and, secondly, the effect of metformin treatment on these

parameters. Twenty-six patients (19 M and 7 F) from neuropsy-

chiatric nursing home “Villa dei pini” (Avellino) were enrolled,

in collaboration with our Department of Psychiatry, University of

Naples SUN. All patients had been diagnosed according to DSM-IV

criteria. They were recruited from July 2013 to January 2015. Cloza-

pine or olanzapine-related hyperglycemia required metformin

introduction in therapy. All prescribed drugs were maintained

at the same therapeutic daily dose during our study. We per-

formed 1, 3 and 6 months follow up after metformin initiation. For

each patient fasting cholesterol, glucose, triglycerides, body weight

(BW), body mass index (BMI), systolic and diastolic blood pressure

(BP) were evaluated. SPSS 16.0 (Statistical Package for Social Sci-

ence) was used for data analysis. After antipsychotic treatment

BMI, fasting glucose and triglycerides were significantly higher

respect to basal values (

P

< 0.01,

P

< 0.0001,

P

< 0.05, respectively).

After metformin treatment, a significant improvement in fasting

glucose, cholesterol and triglycerides was registered (

P

< 0.001).

Conversely, BMI values, althoughnot significant (

P

< 0.168), showed

a trend in increasing. This observational study underlines that

metformin in antipsychotic-treated patients could be useful in pre-

venting clozapine or olanzapine related metabolic abnormalities in

schizophrenic patients.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.2028